Anti-CGRP Migraine Antibodies Show Benefits in Adolescents With Chronic Headache
In 112 adolescents with chronic headache, CGRP monoclonal antibodies reduced headache frequency by 2 days/month with about 30% perceiving significant benefit, and side effects were similar to adults.
Quick Facts
What This Study Found
In 112 adolescents, CGRP mAbs reduced headache frequency by 2.0 days/month (95% CI -0.8 to -3.2). 29.5% perceived significant benefit. 31% reported functional improvement. Side effects were mild and similar to adults. 4.5% discontinued for side effects.
Key Numbers
112 adolescents; mean age 15.9; 26.9 headache days/month baseline; -2.0 days reduction; 29.5% significant benefit; 17% injection site reactions; 4.5% discontinuation
How They Did This
Retrospective multisite cohort study. 112 patients <18 years receiving CGRP mAbs for headache prevention. Demographics, headache characteristics, efficacy, and side effects collected. Mean age 15.9 years. 83.9% chronic migraine.
Why This Research Matters
Adolescents with chronic migraine have very limited treatment options and often miss significant school time. This first evidence of CGRP antibody safety and efficacy in teens could expand treatment access for a vulnerable population.
The Bigger Picture
This study fills a critical evidence gap for pediatric migraine treatment. As CGRP antibodies become established in adult practice, extending their use to adolescents — with appropriate evidence — addresses an underserved patient population.
What This Study Doesn't Tell Us
Retrospective study without a control group. Modest average response (2 fewer days/month from a baseline of 27). Only 30% perceived significant benefit. Short follow-up. Self-selected population with highly refractory headache.
Questions This Raises
- ?Would randomized controlled trials in adolescents confirm this modest benefit?
- ?Can predictors be identified for which adolescents will respond to CGRP antibodies?
- ?Is the lower response rate in adolescents compared to adult trials due to different headache biology or refractory populations?
Trust & Context
- Key Stat:
- 30% benefited About 30% of adolescents with severe chronic headache (averaging 27 days/month) perceived significant benefit from CGRP antibody treatment — the first data supporting their use in teens
- Evidence Grade:
- Low-to-moderate evidence: largest adolescent CGRP antibody cohort published, but retrospective design without control group and modest effect sizes.
- Study Age:
- Published 2021. Formal clinical trials of CGRP antibodies in pediatric/adolescent populations are now underway.
- Original Title:
- Calcitonin Gene-Related Peptide Monoclonal Antibody Use for the Preventive Treatment of Refractory Headache Disorders in Adolescents.
- Published In:
- Pediatric neurology, 114, 62-67 (2021)
- Authors:
- Greene, Kaitlin A, Gentile, Carlyn P, Szperka, Christina L(3), Yonker, Marcy, Gelfand, Amy A, Grimes, Barbara, Irwin, Samantha L
- Database ID:
- RPEP-05417
Evidence Hierarchy
Frequently Asked Questions
Can teenagers get CGRP antibody injections for migraine?
CGRP antibodies are not yet FDA-approved for patients under 18, but this study of 112 adolescents shows they appear safe with similar side effects to adults. About 30% experienced meaningful improvement. Some pediatric neurologists prescribe them off-label for severe cases.
How well do CGRP antibodies work in teens?
The average improvement was modest — about 2 fewer headache days per month from a baseline of 27 days. However, about 30% of patients reported significant benefit. The relatively low response rate may reflect that these were very severe, treatment-resistant cases.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05417APA
Greene, Kaitlin A; Gentile, Carlyn P; Szperka, Christina L; Yonker, Marcy; Gelfand, Amy A; Grimes, Barbara; Irwin, Samantha L. (2021). Calcitonin Gene-Related Peptide Monoclonal Antibody Use for the Preventive Treatment of Refractory Headache Disorders in Adolescents.. Pediatric neurology, 114, 62-67. https://doi.org/10.1016/j.pediatrneurol.2020.09.014
MLA
Greene, Kaitlin A, et al. "Calcitonin Gene-Related Peptide Monoclonal Antibody Use for the Preventive Treatment of Refractory Headache Disorders in Adolescents.." Pediatric neurology, 2021. https://doi.org/10.1016/j.pediatrneurol.2020.09.014
RethinkPeptides
RethinkPeptides Research Database. "Calcitonin Gene-Related Peptide Monoclonal Antibody Use for ..." RPEP-05417. Retrieved from https://rethinkpeptides.com/research/greene-2021-calcitonin-generelated-peptide-monoclonal
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.